At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBM Psyence Biomedical Ltd
Trading 04-08 11:07:26 EDT
2.59
+0.09
+3.60%
High2.60Low2.51Vol9.62K
Open2.60D1 Closing2.50Amplitude3.61%
Mkt Cap2.97MTradable Cap2.51MTotal Shares1.15M
T/O24.84KT/O Rate0.99%Tradable Shares970.70K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Psyence Biomedical Ltd - Expands Australian Clinical Site Network to Five Sites
THOMSON REUTERS  ·  21:16
Psyence Biomedical Ltd - Expands Australian Clinical Site Network to Five Sites
Psyence BioMed expands Australia clinical trial network to five sites for NPX-5 program
Reuters  ·  21:15
Psyence BioMed expands Australia clinical trial network to five sites for NPX-5 program
A Look At Cigna Group’s Valuation After PBM Reform Progress And New CEO Announcement
Simply Wall St.  ·  04-02
A Look At Cigna Group’s Valuation After PBM Reform Progress And New CEO Announcement
Mochi Finance founder offloads 550K CVX as fraud claims deepen across DeFi
cryptonews  ·  03-26
Mochi Finance founder offloads 550K CVX as fraud claims deepen across DeFi
Psyence Group; GoldCoast private placement raises $2.78 million on $0.85 shares
Reuters  ·  03-26
Psyence Group; GoldCoast private placement raises $2.78 million on $0.85 shares
Should FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?
Simply Wall St.  ·  03-26
Should FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?
Psyence Group says GoldCoast raises CAD 5.83 million in financing tied to proposed amalgamation
Reuters  ·  03-18
Psyence Group says GoldCoast raises CAD 5.83 million in financing tied to proposed amalgamation
Psyence BioMed Plans to Advance Vertically Integrated Platform and Product and Clinical Development Program, Targeting Phase IIb Trial Execution and Regulatory Readiness
Reuters  ·  03-11
Psyence BioMed Plans to Advance Vertically Integrated Platform and Product and Clinical Development Program, Targeting Phase IIb Trial Execution and Regulatory Readiness
Psyence Biomedical appoints Sashank Pillay to board after Seth Feuerstein resigns
Reuters  ·  03-11
Psyence Biomedical appoints Sashank Pillay to board after Seth Feuerstein resigns
Corporate Update: Psyence Biomed Advances Vertically Integrated Pharmaceutical Platform Following Psylabs Export Milestone
THOMSON REUTERS  ·  03-11
Corporate Update: Psyence Biomed Advances Vertically Integrated Pharmaceutical Platform Following Psylabs Export Milestone
BRIEF-Psyence Biomed Announces Export Of Gmp-Manufactured Natural Psilocybin (Npx-5) To Australia For Ongoing Phase Iib Clinical Trial
Reuters  ·  03-03
BRIEF-Psyence Biomed Announces Export Of Gmp-Manufactured Natural Psilocybin (Npx-5) To Australia For Ongoing Phase Iib Clinical Trial
Psyence Biomed Announces Export of Gmp-Manufactured Natural Psilocybin (Npx-5) to Australia for Ongoing Phase Iib Clinical Trial
THOMSON REUTERS  ·  03-03
Psyence Biomed Announces Export of Gmp-Manufactured Natural Psilocybin (Npx-5) to Australia for Ongoing Phase Iib Clinical Trial
Psyence Biomedical Names Sashank Pillay to Board After Seth Feuerstein Resigns
Reuters  ·  03-02
Psyence Biomedical Names Sashank Pillay to Board After Seth Feuerstein Resigns
Psyence extends GoldCoast amalgamation deadline to May 31, 2026
Reuters  ·  02-24
Psyence extends GoldCoast amalgamation deadline to May 31, 2026
Psyence BioMed to Invest $5 Million in PsyLabs via Share-for-Share Exchange
Reuters  ·  02-21
Psyence BioMed to Invest $5 Million in PsyLabs via Share-for-Share Exchange
Psyence Biomed Announces Exercise of Put Option by Psylabs and Strategic Equity Investment
THOMSON REUTERS  ·  02-21
Psyence Biomed Announces Exercise of Put Option by Psylabs and Strategic Equity Investment
Press Release: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Dow Jones  ·  02-21
Press Release: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence BioMed Shareholders Approve Up to 250-for-1 Share Consolidation Authority
Reuters  ·  02-19
Psyence BioMed Shareholders Approve Up to 250-for-1 Share Consolidation Authority
Psyence Biomedical announces results of annual, special meeting
TIPRANKS  ·  02-17
Psyence Biomedical announces results of annual, special meeting
Press Release: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Dow Jones  ·  02-17
Press Release: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Introduction

Company Name.
Psyence Biomedical Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.
Issue price:
--